T1	SNP 253 262	variation
T2	Spec 235 252	evaluated whether
T3	Entity 304 308	COMT
T4	Entity 310 316	CYP1A1
T5	Entity 318 324	CYP1B1
T6	Entity 266 271;283 302	genes estrogen metabolism
T7	Entity 326 333	CYP17A1
T8	Entity 335 342	CYP19A1
T9	Entity 344 348	ESR1
T10	Entity 350 355	GSTM1
T11	Entity 357 362	GSTP1
T12	Entity 364 369	GSTT1
T13	Entity 371 378	HSD17B1
T14	Entity 380 387	SULT1A1
T15	Entity 393 399	UGT1A1
T16	Association 401 412	contributes
E1	Association:T16 bc:T17
T17	Cancer 416 429	breast cancer
R1	Speculation_marker Arg1:E1 Arg2:T2	
T19	Entity 757 768	Black women
R2	SNP_coupled_gene Arg1:T1 Arg2:T6	
T20	SNP 909 920	single SNPs
T21	Level 839 853	No appreciable
T22	Association 854 866	associations
E2	Association:T22 bc:T23 snp_int:T20 snp_int2:E3
A1	Level E2 Low
T23	Cancer 872 885	breast cancer
R3	Level_marker Arg1:E2 Arg2:T21	
R4	Member Arg1:T6 Arg2:T3	
R5	Member Arg1:T6 Arg2:T4	
R6	Member Arg1:T6 Arg2:T5	
R7	Member Arg1:T6 Arg2:T7	
R8	Member Arg1:T6 Arg2:T8	
R9	Member Arg1:T6 Arg2:T9	
R10	Member Arg1:T6 Arg2:T10	
R11	Member Arg1:T6 Arg2:T11	
R12	Member Arg1:T6 Arg2:T12	
R13	Member Arg1:T6 Arg2:T13	
R14	Member Arg1:T6 Arg2:T14	
R15	Member Arg1:T6 Arg2:T15	
T18	Interaction 924 934	haplotypes
E3	Interaction:T18 Entity:T20
R17	Member Arg1:T1 Arg2:T20	
T24	Entity 938 943	women
R18	Population_assignment Arg1:T20 Arg2:T24	
T25	SNP 598 629	single nucleotide polymorphisms
R19	Equiv Arg1:T20 Arg2:T25	
T26	Entity 658 673	hormone therapy
T27	SNP 1017 1026	rs1800440
T28	Entity 1009 1015	CYP1B1
R20	SNP_coupled_gene Arg1:T27 Arg2:T28	
T29	Entity 1080 1087	CYP17A1
T30	SNP 1089 1097	rs743572
R21	SNP_coupled_gene Arg1:T30 Arg2:T29	
T31	Entity 1164 1166	HT
R22	Equiv Arg1:T31 Arg2:T26	
T32	Neg 1149 1154	never
R23	Negation_marker Arg1:T31 Arg2:T32	
R24	Risk_Factor Arg1:T27 Arg2:T31	
R25	Risk_Factor Arg1:T30 Arg2:T31	
T33	Effect_Type 1177 1186	decreased
T34	Association 1187 1191	risk
E4	Association:T34 snp_int:T27 snp_int2:T30 bc:T39
A2	Effect_Type E4 Decrease
R26	Effect_type_marker Arg1:E4 Arg2:T33	
T35	Entity 1164 1166;1216 1226	HT ever users
T36	Level 1237 1252	non-significant
T37	Effect_Type 1253 1262	increased
T38	Association 1263 1267	risk
E5	Association:T38 bc:T39 snp_int:T40 snp_int2:T41
A3	Effect_Type E5 Increase
A4	Level E5 Low
T39	Cancer 1195 1208	breast cancer
R27	Effect_type_marker Arg1:E5 Arg2:T37	
R28	Level_marker Arg1:E5 Arg2:T36	
T40	SNP 1017 1026	rs1800440
R29	Risk_Factor Arg1:T40 Arg2:T35	
T41	SNP 1089 1097	rs743572
R30	Risk_Factor Arg1:T41 Arg2:T35	
R31	SNP_coupled_gene Arg1:T41 Arg2:T29	
R32	SNP_coupled_gene Arg1:T40 Arg2:T28	
T42	Entity 442 460	racial differences
R16	Risk_Factor Arg1:T1 Arg2:T42	
T43	Entity 988 993	women
R33	Population_assignment Arg1:T40 Arg2:T43	
R34	Population_assignment Arg1:T27 Arg2:T43	
R35	Population_assignment Arg1:T41 Arg2:T43	
R36	Population_assignment Arg1:T30 Arg2:T43	
T44	Spec 1483 1486	may
T45	Entity 1476 1482	HT use
T46	Association 1487 1493;1498 1504	modify effect
E6	Association:T46 snp_int:T47 bc:T49
T47	SNP 1508 1517	variation
R37	Risk_Factor Arg1:T47 Arg2:T45	
R38	Speculation_marker Arg1:E6 Arg2:T44	
T48	Entity 1521 1543	estrogen-related genes
R39	SNP_coupled_gene Arg1:T47 Arg2:T48	
T49	Cancer 1547 1560	breast cancer
T50	Entity 1584 1589;1600 1605	Black women
T51	Entity 1594 1605	White women
R40	Population_assignment Arg1:T47 Arg2:T50	
R41	Population_assignment Arg1:T47 Arg2:T51	
T52	Spec 1320 1328	evidence
T53	SNP 1335 1338	SNP
T54	SNP 1017 1026	rs1800440
R42	Equiv Arg1:T53 Arg2:T54	
T55	Entity 1359 1365	CYP1B1
R43	SNP_coupled_gene Arg1:T53 Arg2:T55	
T56	Entity 1339 1341	HT
R44	Risk_Factor Arg1:T53 Arg2:T56	
T57	Entity 1369 1380	White women
R45	Population_assignment Arg1:T53 Arg2:T57	
T58	Association 1263 1267	risk
E7	Association:T58 snp_int:T53 bc:T39 snp_int2:T60
R46	Speculation_marker Arg1:E7 Arg2:T52	
T59	Entity 1407 1414	CYP17A1
T60	SNP 1335 1338	SNP
R47	Risk_Factor Arg1:T60 Arg2:T56	
R48	SNP_coupled_gene Arg1:T60 Arg2:T59	
T61	Entity 1418 1429	Black women
R49	Population_assignment Arg1:T60 Arg2:T61	
T62	SNP 1089 1097	rs743572
R50	Equiv Arg1:T60 Arg2:T62	
